Literature DB >> 1311219

Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data.

A van der Gaast1, P Sonneveld, D R Mans, T A Splinter.   

Abstract

Two patients presenting with malignant meningitis resulting from small-cell carcinoma of the lung and with lymphoblastic leukemia, respectively, were treated by intrathecal administration of etoposide. In both cases, this treatment was well tolerated and produced relief of the central nervous system symptoms. Pharmacokinetic data showed that cerebrospinal fluid drug levels of up to 5.2 micrograms/ml were achieved, which were considerably higher than those obtained after i.v. administration of high-dose etoposide.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1311219     DOI： 10.1007/bf00685957

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  8 in total

Review 1.  Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries.

Authors:  W A Bleyer; D G Poplack
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

2.  Brain metastases of lung cancer: excessive toxicity of high dose VP 16 213.

Authors:  P Viens; J L Lagrange; A Thyss; P Ayela; M Frenay; M Schneider
Journal:  Eur J Cancer Clin Oncol       Date:  1988-12

3.  Primary chemotherapy of brain metastasis in small-cell lung cancer.

Authors:  J S Lee; W K Murphy; B S Glisson; H M Dhingra; P Y Holoye; W K Hong
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

4.  Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.

Authors:  P E Postmus; J J Holthuis; H Haaxma-Reiche; N H Mulder; L M Vencken; W J van Oort; D T Sleijfer; H J Sluiter
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

5.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.

Authors:  R N Hitchins; D R Bell; R L Woods; J A Levi
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

6.  Pharmacokinetics of high dose etoposide (VP 16-213).

Authors:  J J Holthuis; P E Postmus; W J Van Oort; B Hulshoff; H Verleun; D T Sleijfer; N H Mulder
Journal:  Eur J Cancer Clin Oncol       Date:  1986-10

7.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

8.  The response of cerebral metastases in small cell lung cancer to systemic chemotherapy.

Authors:  C J Twelves; R L Souhami; P G Harper; C M Ash; S G Spiro; H M Earl; J S Tobias; H Quinn; D M Geddes
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640
  8 in total
  7 in total

Review 1.  Etoposide phosphate, the water soluble prodrug of etoposide.

Authors:  A H Witterland; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1996-10

Review 2.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.

Authors:  Irene Slavc; Elisabeth Schuller; Jutta Falger; Mehmet Günes; Konrad Pillwein; Thomas Czech; Wolfgang Dietrich; Karl Rössler; Karin Dieckmann; Daniela Prayer; Johannes Hainfellner
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

Review 4.  Current diagnosis and treatment of leptomeningeal metastasis.

Authors:  L M DeAngelis
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

5.  Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.

Authors:  Kristian W Pajtler; Stephan Tippelt; Nele Siegler; Stefanie Reichling; Martina Zimmermann; Ruth Mikasch; Udo Bode; Astrid Gnekow; Torsten Pietsch; Martin Benesch; Stefan Rutkowski; Gudrun Fleischhack
Journal:  J Neurooncol       Date:  2016-05-04       Impact factor: 4.130

Review 6.  Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

Authors:  Jörg T Hartmann; Hans-Peter Lipp
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.

Authors:  G Fleischhack; S Reif; C Hasan; U Jaehde; S Hettmer; U Bode
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.